Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology
Top Cited Papers
- 24 September 2013
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Reviews Cancer
- Vol. 13 (10), 685-700
- https://doi.org/10.1038/nrc3580
Abstract
The burgeoning field of anaplastic lymphoma kinase (ALK) in cancer encompasses many cancer types, from very rare cancers to the more prevalent non-small-cell lung cancer (NSCLC). The common activation of ALK has led to the use of the ALK tyrosine kinase inhibitor (TKI) crizotinib in a range of patient populations and to the rapid development of second-generation drugs targeting ALK. In this Review, we discuss our current understanding of ALK function in human cancer and the implications for tumour treatment.This publication has 212 references indexed in Scilit:
- Anaplastic Lymphoma Kinase Is Required for Neurogenesis in the Developing Central Nervous System of ZebrafishPLOS ONE, 2013
- MicroRNA 96 Is a Post-Transcriptional Suppressor of Anaplastic Lymphoma Kinase ExpressionThe American Journal of Pathology, 2012
- ALK and MYCN: When Two Oncogenes Are Better than OneCancer Cell, 2012
- Activated ALK Collaborates with MYCN in Neuroblastoma PathogenesisCancer Cell, 2012
- Fusion Tyrosine Kinase NPM-ALK Deregulates MSH2 and Suppresses DNA Mismatch Repair Function: Novel Insights into a Potent OncoproteinThe American Journal of Pathology, 2011
- NF1 Is a Tumor Suppressor in Neuroblastoma that Determines Retinoic Acid Response and Disease OutcomeCell, 2010
- Cell Signaling by Receptor Tyrosine KinasesCell, 2010
- Defining the conserved internal architecture of a protein kinaseBiochimica et Biophysica Acta (BBA) - Proteins and Proteomics, 2010
- Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAFCell, 2010
- Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survivalCancer, 2004